{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:56:30Z","timestamp":1793372190741,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":427,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1124\/jpet.123.001618","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T20:40:22Z","timestamp":1691700022000},"page":"204-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers"],"prefix":"10.1016","volume":"387","author":[{"given":"Moti","family":"Rosenstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Offman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Will","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Mansbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001618_bib1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: The diagnosis and management","volume":"7","author":"Abd El-Kader","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1124\/jpet.123.001618_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038438","article-title":"Fundamentals of FGF19 & FGF21 action in vitro and in vivo","volume":"7","author":"Adams","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001618_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41366-018-0080-7","article-title":"FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys","volume":"42","author":"Andersen","year":"2018","journal-title":"Int J Obes"},{"key":"10.1124\/jpet.123.001618_bib4","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001618_bib5","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1038\/s41598-020-63726-w","article-title":"FGF21 mimics a fasting-induced metabolic state and increases appetite in zebrafish","volume":"10","author":"Blanco","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.123.001618_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.123.001618_bib7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.123.001618_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1124\/jpet.123.001618_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1021\/bc200478w","article-title":"Analytical measurement of PEGylated molecules","volume":"23","author":"Cheng","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.123.001618_bib10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.123.001618_bib11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/dom.13560","article-title":"FGF21 decreases food intake and body weight in obese G\u00f6ttingen minipigs","volume":"21","author":"Christoffersen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.123.001618_bib12","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.123.001618_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"key":"10.1124\/jpet.123.001618_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001618_bib15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.biochi.2004.09.016","article-title":"Adiponectin, obesity, and cardiovascular disease","volume":"86","author":"Fasshauer","year":"2004","journal-title":"Biochimie"},{"key":"10.1124\/jpet.123.001618_bib16","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001618_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/jpet.123.001618_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41574-018-0030-4","article-title":"Link between FGF21 and blood pressure","volume":"14","author":"Greenhill","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/jpet.123.001618_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.123.001618_bib20","article-title":"A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001618_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jmcb\/mjw013","article-title":"The FGF21-adiponectin axis in controlling energy and vascular homeostasis","volume":"8","author":"Hui","year":"2016","journal-title":"J Mol Cell Biol"},{"key":"10.1124\/jpet.123.001618_bib22","article-title":"Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease","volume":"4","author":"Itoh","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"10.1124\/jpet.123.001618_bib23","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.RA120000767","article-title":"Adiponectin forms a complex with atherogenic LDL and inhibits its downstream effects","volume":"62","author":"Kakino","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.123.001618_bib24","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.123.001618_bib25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.123.001618_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease\u2014an evolving view","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1124\/jpet.123.001618_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/jpet.123.001618_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.molmet.2017.03.009","article-title":"FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue","volume":"6","author":"Markan","year":"2017","journal-title":"Mol Metab"},{"key":"10.1124\/jpet.123.001618_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db11-0838","article-title":"FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents","volume":"61","author":"Mu","year":"2012","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001618_bib30","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/jpet.123.001618_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1124\/jpet.123.001618_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease","volume":"152","author":"Pagano","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1124\/jpet.123.001618_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","article-title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.123.001618_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"10.1124\/jpet.123.001618_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-017-0511-9","article-title":"Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics","volume":"16","author":"Retterst\u00f8l","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1124\/jpet.123.001618_bib36","doi-asserted-by":"crossref","first-page":"45819","DOI":"10.1038\/srep45819","article-title":"Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2\/Nesfatin-1 neurons to produce satiety under fed states","volume":"7","author":"Santoso","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.123.001618_bib37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001618_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.123.001618_bib39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","article-title":"Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"90","author":"Spengler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/jpet.123.001618_bib40","article-title":"FGF19 and FGF21: In NASH we trust","volume":"46","author":"Talukdar","year":"2020","journal-title":"Molec Metab"},{"key":"10.1124\/jpet.123.001618_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.123.001618_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5114\/ceh.2020.102153","article-title":"Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression","volume":"6","author":"Thandra","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"10.1124\/jpet.123.001618_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10928-016-9481-1","article-title":"PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates","volume":"43","author":"Thompson","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.123.001618_bib44","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/bph.15725","article-title":"Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats","volume":"179","author":"Tillman","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001618_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1124\/jpet.123.001618_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.123.001618_bib47","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1073\/pnas.1009427107","article-title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001618_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1124\/jpet.123.001618_bib49","doi-asserted-by":"crossref","first-page":"38592","DOI":"10.18632\/oncotarget.16951","article-title":"Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma","volume":"8","author":"Yoo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.123.001618_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001618_bib51","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00065","article-title":"The starvation hormone, fibroblast growth factor-21, extends lifespan in mice","volume":"1","author":"Zhang","year":"2012","journal-title":"eLife"},{"key":"10.1124\/jpet.123.001618_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:51:35Z","timestamp":1740675095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652417108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S002235652417108X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001618","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}